Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 24, 2009

Two U.K. Institutes Join GeneGo’s MetaMiner CNS Partnership Program

  • The NIHR Biomedical Research Centre for Mental Health and King's College London (BRC-MH) have joined GeneGo’s MetaMiner CNS Partnership Program. The goal is to develop a central nervous system (CNS) pathway-analysis platform, which includes developing a series of disease pathway maps for schizophrenia, Alzheimer’s disease, and Huntington's disease. The program will also leverage experimental data from the public domain and make it available for analysis.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »